We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Celanese (CE) & Glaukos Join Forces for Glaucoma Treatment
Read MoreHide Full Article
Celanese Corporation (CE - Free Report) has signed a deal with Glaukos Corporation to supply its VitalDose Drug Delivery Platform. This platform will be included in Glaukos’ iDose TR, a micro-invasive intraocular implant designed to decrease intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
The iDose TR aims to address the problem of non-adherence to topical medications and associated chronic side effects by providing continuous, long-lasting therapy for 24 hours a day. Currently, Glaukos is awaiting approval by the U.S. Food and Drug Administration of the New Drug Application it submitted for iDose TR in February 2023.
Treating glaucoma through sustained delivery of therapeutics has gained significant importance over time. The VitalDose Drug Delivery Platform offers a promising solution by enabling continuous dosing, which can effectively mitigate challenges related to patient compliance and adherence.
Celanese stated that its mission to enhance the health of individuals with chronic eye diseases in the field of ophthalmology is furthered by integrating the VitalDose Platform into Glaukos' iDose TR therapy. The company is also enthusiastic about assisting Glaukos in its efforts to introduce iDose TR to patients seeking a new alternative to glaucoma treatment.
Shares of Celanese have lost 24.4% over a year compared with a 5.6% fall recorded by its industry.
Image Source: Zacks Investment Research
CE, on its fourth-quarter call, said that it expects growth in its quarterly earnings through 2023 on an improvement in demand and the synergies resulting from the Mobility & Materials acquisition. Factoring in all this, it expects its adjusted earnings to be in the range of $1.50-$1.75 per share for the first quarter of 2023.
Olympic Steel’s shares have gained 35.6% in the past year. The Zacks Consensus Estimate for ZEUS’ current-year earnings has been revised 33.1% upward in the past 60 days. It topped the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 26.2% on average.
Steel Dynamic’s shares have gained 23.4% in the past year. The Zacks Consensus Estimate for STLD’s current-year earnings has been revised 31% upward in the past 60 days. It topped the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 11.3% on average.
Linde’s shares have gained 11.8% in the past year. The company has an expected earnings growth rate of 8.1% for the current year. The Zacks Consensus Estimate for LIN’s current-year earnings has been revised 2.5% upward in the past 60 days.
LIN topped the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 6% on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Celanese (CE) & Glaukos Join Forces for Glaucoma Treatment
Celanese Corporation (CE - Free Report) has signed a deal with Glaukos Corporation to supply its VitalDose Drug Delivery Platform. This platform will be included in Glaukos’ iDose TR, a micro-invasive intraocular implant designed to decrease intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension.
The iDose TR aims to address the problem of non-adherence to topical medications and associated chronic side effects by providing continuous, long-lasting therapy for 24 hours a day. Currently, Glaukos is awaiting approval by the U.S. Food and Drug Administration of the New Drug Application it submitted for iDose TR in February 2023.
Treating glaucoma through sustained delivery of therapeutics has gained significant importance over time. The VitalDose Drug Delivery Platform offers a promising solution by enabling continuous dosing, which can effectively mitigate challenges related to patient compliance and adherence.
Celanese stated that its mission to enhance the health of individuals with chronic eye diseases in the field of ophthalmology is furthered by integrating the VitalDose Platform into Glaukos' iDose TR therapy. The company is also enthusiastic about assisting Glaukos in its efforts to introduce iDose TR to patients seeking a new alternative to glaucoma treatment.
Shares of Celanese have lost 24.4% over a year compared with a 5.6% fall recorded by its industry.
Image Source: Zacks Investment Research
CE, on its fourth-quarter call, said that it expects growth in its quarterly earnings through 2023 on an improvement in demand and the synergies resulting from the Mobility & Materials acquisition. Factoring in all this, it expects its adjusted earnings to be in the range of $1.50-$1.75 per share for the first quarter of 2023.
Celanese Corporation Price and Consensus
Celanese Corporation price-consensus-chart | Celanese Corporation Quote
Zacks Rank & Key Picks
Celanese currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the basic materials space are Olympic Steel, Inc. (ZEUS - Free Report) , Steel Dynamics, Inc. (STLD - Free Report) and Linde plc (LIN - Free Report) . LIN currently carries a Zacks Rank #2 (Buy), while ZEUS and STLD sport a Zacks Rank #1(Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Olympic Steel’s shares have gained 35.6% in the past year. The Zacks Consensus Estimate for ZEUS’ current-year earnings has been revised 33.1% upward in the past 60 days. It topped the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 26.2% on average.
Steel Dynamic’s shares have gained 23.4% in the past year. The Zacks Consensus Estimate for STLD’s current-year earnings has been revised 31% upward in the past 60 days. It topped the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 11.3% on average.
Linde’s shares have gained 11.8% in the past year. The company has an expected earnings growth rate of 8.1% for the current year. The Zacks Consensus Estimate for LIN’s current-year earnings has been revised 2.5% upward in the past 60 days.
LIN topped the Zacks Consensus Estimate in all the last four quarters. It delivered a trailing four-quarter earnings surprise of 6% on average.